Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
Status:
Terminated
Trial end date:
2017-03-16
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study designed for the purpose of estimating various parameters surrounding
the efficacy of Clofarabine, Cyclophosphamide and Etoposide in eliminating minimal residual
disease (MRD) in acute leukemia patients otherwise in remission and without causing
significant delay of HCT due to treatment related toxicity.
A single course of "bridge" chemotherapy is given prior to the transplant procedure as an
approach to improved disease-free survival in a patient group who historically has had
inferior outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
American Family Children's Hospital American Family Children’s Hospital Nationwide Children's Hospital